Press release
Mucopolysaccharidosis Type I Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Mucopolysaccharidosis Type I Pipeline. Dive into DelveInsight's comprehensive report today! @ Mucopolysaccharidosis Type I Pipeline Outlook [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Mucopolysaccharidosis Type I Pipeline Report
* In May 2025, JCR Pharmaceuticals Co. Ltd announced a JR-171-101 study (NCT04227600) and fulfill all eligibility criteria can be enrolled in this JR-171-102 study. In the JR-171-102 study, subjects will receive either 2.0 or 4.0 mg/kg/week of JR-171 intravenously at the same doses received at Week 12 of the JR-171-101 study.
* DelveInsight's Mucopolysaccharidosis Type I Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Mucopolysaccharidosis Type I treatment.
* The leading Mucopolysaccharidosis Type I Companies such as Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Promising Mucopolysaccharidosis Type I Pipeline Therapies such as Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
Stay ahead with the most recent pipeline outlook for Mucopolysaccharidosis Type I. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Mucopolysaccharidosis Type I Treatment Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Emerging Drugs Profile
* OTL 203: Orchard Therapeutics
OTL-203 is an investigational ex vivo autologous gene therapy being investigated for the treatment of MPS-I. It uses a modified virus to insert a functional copy of the IDUA gene into a patient's cells. OTL-203 is being developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy. OTL-203 has received rare pediatric disease designation from the FDA. Through an ongoing proof-of-concept clinical trial, OTL-203 is being evaluated as a potential treatment for patients with the most severe form of MPS-I, known as Hurler syndrome. OTL-203 is an investigational therapy and has not been approved by any regulatory agency or health authority. Currently, the drug is in Phase III stage of its development for the treatment of Mucopolysaccharidosis Type I.
* JR 171: JCR Pharmaceuticals
JR-171, is an investigational drug for the treatment of mucoplysaccharidosis type I (MPS I, or Hurler, Hurler-Scheie and Scheie syndrome). JR-171 is a blood-brain-barrier (BBB)-penetrating form recombinant -L-iduronidase that was developed using JCR's proprietary J-Brain Cargo Registered BBB technology. JR-171 received the orphan drug designation from the US Food Drug Administration (FDA) in February 2021. The trial is also scheduled for enrolling patients in the US. Currently, the drug is in Phase I/II stage of its development for the treatment of Mucopolysaccharidosis Type I.
The Mucopolysaccharidosis Type I Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Mucopolysaccharidosis Type I with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mucopolysaccharidosis Type I Treatment.
* Mucopolysaccharidosis Type I Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Mucopolysaccharidosis Type I Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mucopolysaccharidosis Type I market
Explore groundbreaking therapies and clinical trials in the Mucopolysaccharidosis Type I Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Mucopolysaccharidosis Type I Drugs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Mucopolysaccharidosis Type I Companies
Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
Mucopolysaccharidosis type I (MPS I) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Mucopolysaccharidosis Type I Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Mucopolysaccharidosis Type I Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Mucopolysaccharidosis Type I Market Drivers and Barriers [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Mucopolysaccharidosis Type I Market Report
* Coverage- Global
* Mucopolysaccharidosis Type I Companies- Orchard Therapeutics, JCR Pharmaceuticals, REGENXBIO and others.
* Mucopolysaccharidosis Type I Pipeline Therapies- Laronidase, Antihistamine, Antipyretic, JR-171, AGT-181, Cyclosporine A (CsA), Azathioprine (Aza), RGX-111, SBC-103 , and others.
* Mucopolysaccharidosis Type I Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Mucopolysaccharidosis Type I Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Mucopolysaccharidosis Type I Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mucopolysaccharidosis Type I Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/mucopolysaccharidosis-type-i-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Mucopolysaccharidosis type I (MPS I): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Mucopolysaccharidosis type I (MPS I)- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* OTL 203: Orchard Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* JR 171: JCR Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Mucopolysaccharidosis type I (MPS I) Key Products
* Mucopolysaccharidosis type I (MPS I)- Unmet Needs
* Mucopolysaccharidosis type I (MPS I)- Market Drivers and Barriers
* Mucopolysaccharidosis type I (MPS I)- Future Perspectives and Conclusion
* Mucopolysaccharidosis type I (MPS I) Analyst Views
* Mucopolysaccharidosis type I (MPS I) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mucopolysaccharidosis-type-i-pipeline-appears-robust-with-8-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/mucopolysaccharidosis-type-i-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Type I Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4026998 • Views: …
More Releases from ABNewswire
Jamaica Welcomes Travelers Back: Five Sandals and Beaches Negril Resort Fully Op …
Sandals Resorts Announces Complete Reopening of Five Jamaica Properties Following October Hurricane
Jamaica's tourism industry is thriving once again as the island destination confirms Five Sandals and Beaches resort properties have fully reopened following Hurricane impacts in October 2025. Travelers planning Caribbean vacations can now book with confidence as Jamaica's world-renowned hospitality and pristine beaches welcome visitors back.
All Five Sandals and Beaches Jamaica Resorts Now Open
Sandals Resorts International has confirmed that…
Asset Optimization Solutions Market to Reach USD 9.6 Billion by 2030, Driven by …
Mordor Intelligence has published a new report on the asset optimization solutions market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Asset Optimization Solutions Market Overview
The asset optimization solutions market reached USD 5.45 billion in 2025 and is projected to grow to USD 9.6 billion by 2030, supported by strong interest in predictive maintenance, cloud-based asset management platforms, and deeper industrial IoT connectivity. As industries modernize equipment management…
Massage Minneapolis by Halo Healing Therapies Co.: Serving Golden Valley, St. Lo …
Halo Healing Therapies Co. in North Loop Minneapolis provides expert therapeutic massage for clients across Golden Valley, St. Louis Park, Hopkins & New Hope. With over 25 years of experience, Halo offers deep tissue, couples, sports, and restorative massage tailored to the active Minneapolis lifestyle. Conveniently located near landmarks like Brookview Park, The West End, Mainstreet Hopkins, and Northwood Park, Halo delivers care that relieves tension, supports recovery, & enhances…
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg
The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence.
A clearer view of pentest vs red team helps organisations make better…
More Releases for Mucopolysaccharidosis
Mucopolysaccharidosis Treatment Market Trends That Will Shape the Next Decade: I …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Mucopolysaccharidosis Treatment Market Size By 2025?
The market for treatments for mucopolysaccharidosis has experienced robust expansion recently, projected to climb from a valuation of $2.4 billion in 2024 to $2.58 billion by 2025, reflecting a compound annual growth rate of 7.7%; this uptrend during the…
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Mucopolysaccharidosis Market Set to Hit USD 3.65 Billion by 2034
Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the absence or malfunction of enzymes needed to break down glycosaminoglycans (GAGs). These conditions, including Hurler syndrome (MPS I), Hunter syndrome (MPS II), Sanfilippo syndrome (MPS III), and others, are progressive and can affect physical and cognitive development.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71067
Over the past decade, orphan drug development, advancements in enzyme replacement therapy…
Mucopolysaccharidosis Treatment Market Analysis, Keyplayers, Share And Forecast …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Mucopolysaccharidosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.19 billion In 2028 At…
Mucopolysaccharidosis Treatment Market Size, Trends, Leading Players, Share And …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Mucopolysaccharidosis Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mucopolysaccharidosis treatment market size has grown strongly in recent years. It…
Gene Therapy for Mucopolysaccharidosis Market to Witness Growth Acceleration by …
Gene Therapy for Mucopolysaccharidosis Market is expected to witness moderate growth registering 9.4% CAGR during the forecast period (2023-2029).
Important changes in the business allow key players to attain larger profits. This Gene Therapy for Mucopolysaccharidosis Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry. Furthermore, this market report makes…
